| Browse All

BriaCell Therapeutics Corp. (BCTXZ)

West Vancouver, Canada | NasdaqCM
0.14 USD +0.01 (4.392%) ⇧ (April 17, 2026, 4 p.m. EDT)

Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 9:48 p.m. EDT

High-risk speculative trap: Despite a potential Phase 3 treatment milestone and strong balance sheet liquidity, the stock is trading at a negligible fraction of book value (-89% ROA) with no dividend history and zero directional forecast for the next 45 days, rendering it unsuitable for capital preservation.

None
Attribute Value
Beta 1.63
Website https://briacell.com

Info Dump

Attribute Value
Address1 Bellevue Centre
Address2 Suite 300 235 -15th Street
Ask 1.45
Ask Size 1
Beta 1.626
Bid 0.928
Bid Size 1
Book Value 4.264
City West Vancouver
Compensation As Of Epoch Date 1,767,139,200
Country Canada
Crypto Tradeable 0
Currency USD
Current Price 0.1426
Current Ratio 10.102
Custom Price Alert Confidence HIGH
Day High 0.15
Day Low 0.13
Display Name BriaCell Therapeutics
Ebitda -30,630,110
Ebitda Margins 0.0
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 604 921 1898
Fifty Two Week High 0.15
Fifty Two Week High Change -0.007400006
Fifty Two Week High Change Percent -0.04933337
Fifty Two Week Low 0.13
Fifty Two Week Low Change 0.012600005
Fifty Two Week Low Change Percent 0.09692311
Fifty Two Week Range 0.13 - 0.15
Financial Currency USD
First Trade Date Milliseconds 1,772,807,400,000
Float Shares 6,410,301
Free Cashflow -20,493,214
Full Exchange Name NasdaqCM
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,025-04-25
Language en-US
Long Business Summary BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Long Name BriaCell Therapeutics Corp.
Market us_market
Market State CLOSED
Max Age 86,400
Message Board Id finmb_262266102
Net Income To Common -29,637,656
Open 0.1479
Operating Cashflow -30,967,316
Operating Margins 0.0
Phone 604 921 1810
Previous Close 0.1366
Price Hint 4
Price To Book 0.033442777
Profit Margins 0.0
Quick Ratio 9.387
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0059999973
Regular Market Change Percent 4.3923845
Regular Market Day High 0.15
Regular Market Day Low 0.13
Regular Market Day Range 0.13 - 0.15
Regular Market Open 0.1479
Regular Market Previous Close 0.1366
Regular Market Price 0.1426
Regular Market Time 1,776,456,000
Regular Market Volume 4,635
Return On Assets -0.89438003
Return On Equity -1.7920799
Sand P52 Week Change 0.38150132
Sector
Sector Key
Short Name BriaCell Therapeutics Corp. War
Source Interval 15
State BC
Symbol BCTXZ
Total Cash 29,903,628
Total Cash Per Share 4.124
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 4,635
Website https://briacell.com
Zip V7T 2X1